The study included pre-treatment melanoma biopsies from 36 patients subsequently treated with anti-PD-1 (17/36, 47%) or combination (anti-PD-1 plus anti-CTLA-4) immunotherapy (19/36, 53%) (Table 1 and Figure 1a). The gene discussed is PDCD1; the disease is melanoma.